Anthera Pharmaceutical ... -80%
This is biotech "at its best".
An expert review board gave this drug an approval of passing, with a shelf offering of about $100 millions.
And now ... Sollpura has just failed to achieve the desired results in a Phase 3 clinical study ...
Luckily, I closed one trade with a win for this stock.
Conclusion: Stay away from small biotech firms!
An expert review board gave this drug an approval of passing, with a shelf offering of about $100 millions.
And now ... Sollpura has just failed to achieve the desired results in a Phase 3 clinical study ...
Luckily, I closed one trade with a win for this stock.
Conclusion: Stay away from small biotech firms!
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.